Eli Lilly and Company $LLY is Handelsbanken Fonder AB’s 6th Largest Position

Handelsbanken Fonder AB raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.5% in the 2nd quarter, Holdings Channel.com reports. The firm owned 759,820 shares of the company’s stock after acquiring an additional 25,944 shares during the quarter. Eli Lilly and Company comprises 2.1% of Handelsbanken Fonder AB’s holdings, making the stock its 6th biggest holding. Handelsbanken Fonder AB’s holdings in Eli Lilly and Company were worth $592,302,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company during the 1st quarter valued at $27,000. Financial Gravity Companies Inc. bought a new stake in shares of Eli Lilly and Company during the second quarter valued at about $31,000. Blume Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares in the last quarter. IMG Wealth Management Inc. purchased a new position in Eli Lilly and Company during the second quarter valued at approximately $35,000. Finally, TD Capital Management LLC lifted its stake in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.6%

NYSE LLY opened at $1,042.86 on Friday. The firm has a market capitalization of $985.90 billion, a PE ratio of 68.16, a P/E/G ratio of 1.21 and a beta of 0.43. The stock’s 50 day moving average is $849.83 and its 200 day moving average is $786.02. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,057.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the business earned $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Guggenheim restated a “buy” rating and set a $948.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 16th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Finally, DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,027.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.